TEMOZOLOMIDE CAPSULE 100MG
| Generic Name | Temozolomide |
| Strength | 100 mg |
| Dosage Form | Capsule |
| Route of Administration | Oral |
| Therapeutic Class | Anticancer/Alkylating Agent |
| Indications | Glioblastoma multiforme, anaplastic astrocytoma |
| Prescription Required | Yes |
| Administration | Taken on an empty stomach as prescribed |
| Storage | Store below 30°C and protect from moisture and light |
| Manufacturer | As per the pack details |
TEMOZOLOMIDE CAPSULE 100MG
Temozolomide Capsule 100mg is a prescription oral chemotherapy medicine classified as an alkylating agent. It is primarily prescribed for the treatment of specific brain tumors, including glioblastoma multiforme and anaplastic astrocytoma. This medication is widely recognized in oncology for its ability to target cancer cells effectively.
Temozolomide 100 mg Capsule works by damaging the DNA of cancer cells, disrupting their ability to multiply and grow. Interfering with the tumor’s cellular processes, it helps slow disease progression and improves the effectiveness of combination therapy when used alongside other cancer treatments.
Administered orally under strict medical supervision, Temozolomide 100 mg Capsule offers patients a convenient chemotherapy option. Oncologists determine the appropriate dosage and treatment schedule based on individual patient needs to maximize therapeutic benefits while monitoring for potential side effects of the product.
Product Features
- Alkylating agent oral chemotherapy
- Used in malignant brain tumors
- Interferes with cancer cell DNA replication
- Convenient oral capsule dosage
- Suitable for long-term or cyclic therapy
- Prescription-only oncology medication
How It Helps
- Damages the DNA of cancer cells, preventing their growth and multiplication
- Effective in treating malignant brain tumors like glioblastoma and anaplastic astrocytoma
- Slows the progression of aggressive brain cancers
- Supports long-term or cyclic chemotherapy plans under medical supervision

Reviews
There are no reviews yet.